Multiple Sclerosis Journal · 1995 · 16 citations · 10 references
Life SciencesNeurologyPharmacotherapyImmunopathologyImmunotherapyNeuroimmunologyDemyelinating DiseasesDemyelinating DisordersInterferon-based TherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyControl Group DesignMatched Control GroupMultiple Sclerosis TherapyRelapsing-remitting Multiple Sclerosis Treatment
Preliminary results of a multicenter, randomized study on the effect of natural interferon beta (n-INFN-beta) in relapsing-remitting MS are reported. Sixty patients received either no treatment or n-IFN-beta (9 MIU three times a week, subcutaneously). After 6 months, the n-IFN-beta-treated group showed a 58% median reduction in the number of active lesions detected on monthly magnetic resonance imaging scans as well as a 38% reduction in the exacerbation rate as compared with the control group. Side-effects were mild and self-limiting. The study continues according to the protocol.
10
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Neurology · 1993 · 2.1K citations
Pharmacy, Neurology, Pharmacotherapy +14
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
D. W. Paty, D.K.B. Li · Neurology · 1993 · 2K citations · Full text
Pharmacy, Neurology, Pharmacotherapy +14
Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis
Lawrence Jacobs, Judith A. O’Malley, Arnold I. Freeman et al. · Science · 1981 · 210 citations